Hyperion DeFi (HYPD) Competitors

$3.62 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.66 +0.03 (+0.97%)

As of 05/22/2026 07:38 PM Eastern

HYPD vs. ENLV, HRTX, ORMP, KPTI, and MENS

Should you buy Hyperion DeFi stock or one of its competitors? MarketBeat compares Hyperion DeFi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperion DeFi include Enlivex Therapeutics (ENLV), Heron Therapeutics (HRTX), Oramed Pharmaceuticals (ORMP), Karyopharm Therapeutics (KPTI), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry.

How does Hyperion DeFi compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Enlivex Therapeutics' return on equity of 248.08% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Hyperion DeFi	N/A	-91.59%	-73.08%

Enlivex Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 2,199.65%. Hyperion DeFi has a consensus price target of $5.88, indicating a potential upside of 62.29%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Hyperion DeFi had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 1 mentions for Hyperion DeFi and 0 mentions for Enlivex Therapeutics. Hyperion DeFi's average media sentiment score of 0.54 beat Enlivex Therapeutics' score of 0.37 indicating that Hyperion DeFi is being referred to more favorably in the news media.

Company	Overall Sentiment
Enlivex Therapeutics	Neutral
Hyperion DeFi	Positive

Enlivex Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market.

Enlivex Therapeutics has higher earnings, but lower revenue than Hyperion DeFi. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Hyperion DeFi	$810K	67.75	-$45.31M	-$9.95	N/A

Summary

Hyperion DeFi beats Enlivex Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Hyperion DeFi compare to Heron Therapeutics?

Hyperion DeFi (NASDAQ:HYPD) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Hyperion DeFi currently has a consensus price target of $5.88, suggesting a potential upside of 62.29%. Heron Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 423.99%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Heron Therapeutics has higher revenue and earnings than Hyperion DeFi. Heron Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	67.75	-$45.31M	-$9.95	N/A
Heron Therapeutics	$154.90M	1.05	-$20.19M	-$0.18	N/A

Hyperion DeFi has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Hyperion DeFi's return on equity of -91.59% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Hyperion DeFi has a beta of 2.57, indicating that its share price is 157% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

In the previous week, Hyperion DeFi and Hyperion DeFi both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 0.87 beat Hyperion DeFi's score of 0.54 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Hyperion DeFi and Heron Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Oramed Pharmaceuticals?

Hyperion DeFi (NASDAQ:HYPD) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 1 mentions for Hyperion DeFi. Hyperion DeFi's average media sentiment score of 0.54 beat Oramed Pharmaceuticals' score of 0.11 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals has higher revenue and earnings than Hyperion DeFi. Hyperion DeFi is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	67.75	-$45.31M	-$9.95	N/A
Oramed Pharmaceuticals	$2M	81.66	$64.05M	$2.59	1.54

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oramed Pharmaceuticals' return on equity of -5.37% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

Hyperion DeFi has a beta of 2.57, meaning that its share price is 157% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Hyperion DeFi presently has a consensus target price of $5.88, suggesting a potential upside of 62.29%. Given Hyperion DeFi's stronger consensus rating and higher probable upside, research analysts clearly believe Hyperion DeFi is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oramed Pharmaceuticals beats Hyperion DeFi on 9 of the 16 factors compared between the two stocks.

How does Hyperion DeFi compare to Karyopharm Therapeutics?

Hyperion DeFi (NASDAQ:HYPD) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Hyperion DeFi has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Hyperion DeFi presently has a consensus target price of $5.88, indicating a potential upside of 62.29%. Karyopharm Therapeutics has a consensus target price of $17.17, indicating a potential upside of 110.38%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Hyperion DeFi and Hyperion DeFi both had 1 articles in the media. Hyperion DeFi's average media sentiment score of 0.54 beat Karyopharm Therapeutics' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hyperion DeFi has a beta of 2.57, indicating that its share price is 157% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hyperion DeFi has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	67.75	-$45.31M	-$9.95	N/A
Karyopharm Therapeutics	$146.07M	1.27	-$196.04M	-$15.09	N/A

Summary

Hyperion DeFi beats Karyopharm Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Hyperion DeFi compare to Jyong Biotech?

Hyperion DeFi (NASDAQ:HYPD) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Hyperion DeFi presently has a consensus price target of $5.88, suggesting a potential upside of 62.29%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, equities research analysts clearly believe Hyperion DeFi is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has lower revenue, but higher earnings than Hyperion DeFi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	67.75	-$45.31M	-$9.95	N/A
Jyong Biotech	N/A	N/A	N/A	N/A	N/A

Jyong Biotech's return on equity of 0.00% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Jyong Biotech	N/A	N/A	N/A

25.8% of Hyperion DeFi shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Hyperion DeFi and Hyperion DeFi both had 1 articles in the media. Hyperion DeFi's average media sentiment score of 0.54 beat Jyong Biotech's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperion DeFi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jyong Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Hyperion DeFi beats Jyong Biotech on 8 of the 10 factors compared between the two stocks.

Get Hyperion DeFi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPD vs. The Competition

Export

Metric	Hyperion DeFi	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$54.87M	$470.59M	$6.46B	$12.34B
Dividend Yield	N/A	3.87%	2.76%	5.28%
P/E Ratio	-0.36	3.86	21.21	25.65
Price / Sales	67.75	7,288.62	554.38	86.31
Price / Cash	N/A	13.13	43.49	56.67
Price / Book	0.94	84.78	10.37	7.14
Net Income	-$45.31M	-$96.07M	$3.57B	$335.98M
7 Day Performance	5.54%	0.05%	6.40%	4.15%
1 Month Performance	-13.19%	0.57%	3.53%	2.54%
1 Year Performance	104.52%	63.42%	34.04%	35.06%

Hyperion DeFi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPD Hyperion DeFi	3.0236 of 5 stars	$3.62 flat	$5.88 +62.3%	+104.5%	$54.87M	$810K	N/A	40	Gap Up
ENLV Enlivex Therapeutics	2.2923 of 5 stars	$0.70 0.0%	$16.50 +2,267.3%	-26.4%	$165.45M	N/A	N/A	70	Gap Up
HRTX Heron Therapeutics	2.4568 of 5 stars	$0.87 +1.1%	$4.50 +417.8%	-53.6%	$164.48M	$150.71M	N/A	300	Gap Up
ORMP Oramed Pharmaceuticals	1.8798 of 5 stars	$4.07 -5.2%	N/A	+88.2%	$164.27M	$2M	2.73	10	Gap Up
KPTI Karyopharm Therapeutics	2.4886 of 5 stars	$7.14 +0.0%	$17.17 +140.3%	+77.8%	$162.27M	$146.07M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPD) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperion DeFi (HYPD) Competitors

HYPD vs. ENLV, HRTX, ORMP, KPTI, and MENS

How does Hyperion DeFi compare to Enlivex Therapeutics?

Summary

How does Hyperion DeFi compare to Heron Therapeutics?

Summary

How does Hyperion DeFi compare to Oramed Pharmaceuticals?

Summary

How does Hyperion DeFi compare to Karyopharm Therapeutics?

Summary

How does Hyperion DeFi compare to Jyong Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperion DeFi (HYPD) Competitors

HYPD vs. ENLV, HRTX, ORMP, KPTI, and MENS

How does Hyperion DeFi compare to Enlivex Therapeutics?

Do insiders & institutionals have more ownership in ENLV or HYPD?

Is ENLV or HYPD more profitable?

Do analysts rate ENLV or HYPD?

Does the media refer more to ENLV or HYPD?

Which has more volatility and risk, ENLV or HYPD?

Which has preferable earnings & valuation, ENLV or HYPD?

Summary

How does Hyperion DeFi compare to Heron Therapeutics?

Do analysts rate HYPD or HRTX?

Which has preferable valuation and earnings, HYPD or HRTX?

Is HYPD or HRTX more profitable?

Do insiders and institutionals hold more shares of HYPD or HRTX?

Which has more volatility & risk, HYPD or HRTX?

Does the media favor HYPD or HRTX?

Summary

How does Hyperion DeFi compare to Oramed Pharmaceuticals?

Does the media refer more to HYPD or ORMP?

Which has preferable earnings and valuation, HYPD or ORMP?

Do institutionals and insiders believe in HYPD or ORMP?

Is HYPD or ORMP more profitable?

Which has more volatility and risk, HYPD or ORMP?

Do analysts rate HYPD or ORMP?

Summary

How does Hyperion DeFi compare to Karyopharm Therapeutics?

Is HYPD or KPTI more profitable?

Do analysts prefer HYPD or KPTI?

Does the media refer more to HYPD or KPTI?

Which has more risk & volatility, HYPD or KPTI?

Do insiders & institutionals have more ownership in HYPD or KPTI?

Which has stronger valuation and earnings, HYPD or KPTI?

Summary

How does Hyperion DeFi compare to Jyong Biotech?

Do analysts recommend HYPD or MENS?

Which has stronger earnings and valuation, HYPD or MENS?

Is HYPD or MENS more profitable?

Do institutionals & insiders believe in HYPD or MENS?

Does the media refer more to HYPD or MENS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPD vs. The Competition

Hyperion DeFi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools